Chronic myelogenous leukemia (CML) is a myeloproliferative disorder characterized by increased proliferation of the granulocytic cell line within the bone marrow without losing cells' capacity to differentiate, which is reflected by the increased number of granulocytes and their immature precursor in the peripheral blood. 1 The clinical presentation of CML varies, up to 40% of the patients are asymptomatic at presentation. symptomatic patients can present with different complaints such as fatigue, malaise, weight loss, excessive sweating, abdominal fullness, and bleeding episodes due to platelet dysfunction. 2 On a few rare occasions, CML can present initially with soft tissue hematoma, this can be managed by treatment with tyrosine kinase inhibitors as well as conservative measures. 3